THE TAPE
ATRC · Medical Instruments · $2.8B

AtriCure, Inc.

$55.31▼ −2.69%
Last close
Relative strength
95RS
of 99, against every stock▼ -1 on the month
Cooling off
Unconfirmed
+48.0%
six months against Medical Instruments
52-week range
−16.2%
from the high
$25.36$66.02
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth FLATProof SHOWN
Quarter to Sep 30, revenue +15% on a year ago
Why it is on no screen

ATRC passes every check below but is not on a screen — the screens also require the base to be the most recent structure, which this one is not.

A base has formed23.8 weeks, from 25.36 to 38.32.
Long enough to count23.8 weeks against 3 needed.
Shallow enough33.8% deep against 35% allowed.
Close to its pivot+44.3% from the pivot; listed down to -20%.
Relative strengthRS 95 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
$37.25
-32.7% · tested 3× · last 72 sessions ago
Resistance above
$57.91
+4.7% · tested 4× · last 2 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

AtriCure, Inc. is not on any of the screens right now. Its relative strength rating is 95, and it sits in Medical Instruments.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against its industry
-5.3%
Three months against its industry
+20.7%
Six months against its industry
+48.0%

Read against an equal-weighted index of Medical Instruments, which is +31.0% against the S&P 500 over six months Fully aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 8.0% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$589.8M
+15.0% year on year
Operating margin
2.9%
gross 76.7%
Net margin
2.5%
Free cash flow
$52.9M
1.9% of market cap
Price to sales
4.77×
Price to earnings
189.0×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 3
Key takeaway
Profitable and cash generating; the question is growth.
Revenue
$154.4M
+0.6% QoQ · +15.0% YoY
Gross margin
77.3%
+0.1 pts QoQ
Net income
$4.1M
Positive
Free cash flow
$23.9M
Cash generating

What the numbers say

  • Revenue +15.0% year over year, +0.6% on the quarter
  • Gross margin 77.3%, +0.1 points on the quarter
  • Good: Profitable: net income $4M, operating margin 2.8%
  • Good: Cash generating: operating cash flow $30M, free cash flow $24M
  • Good: Net cash $126M · cash $187M
Revenue by quarter
Free cash flow
Net income
shares +4.0% in a year · net cash $126.0M

The desk’s own read

Flagged as drifting up since the report

Final read
Growth: FLAT · Economic proof: SHOWN
Key question: Can the cash generation hold as growth slows?
The next test is whether the quarter repeats.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

None of the tracked funds held or sold it in their latest filings.

Flagged by the market sweep
Pulled back while its group leadsTape · 2026-11-10
3 lower closes in a leading group, 50d held, at 57.78
Mixed: stocks have lagged random stocks by 1.0% over three sessions, not consistently enough to call (433 cases over 59 nights). Against their own sector they have lagged by 0.9%.
GappedTape · 2026-11-06
-6.5%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ down on earningsTape · 2026-11-06
-6.5% on earnings 2026-11-04
No measurable effect: stocks behave like random ones over the next three sessions (665 cases over 44 nights).
GappedTape · 2026-11-05
+8.5%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ up on earningsTape · 2026-11-05
+8.5% on earnings 2026-11-03
No measurable effect: stocks behave like random ones over the next three sessions (604 cases over 42 nights).
Reported resultsFiling · 2026-11-04
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-04
above 20d & 50d on 1.8x volume at 60.41
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
Earnings comingEvent · 2026-11-03
reports 2026-11-03 amc
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news

No headlines for this company in the last couple of weeks.

Insiders
Bought on the open market
0
Sold on the open market
10
$3,317,897 total

Sold: Privitera Salvatore, GROVES REGINA E, Dahlquist Karl S., Prange Karen, Yuen Maggie, Noznesky Justin J, Doraiswamy Vinayak, WEHRWEIN SVEN.

Not counted above: 8 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-09-23 Privitera Salvatore · Chief Technical Officersell4,519$271,140
2026-09-11 GROVES REGINA E · Directorsell5,313$288,071
2026-09-08 Privitera Salvatore · Chief Technical Officersell3,657$201,135
2026-09-02 Privitera Salvatore · Chief Technical Officersell7,763$407,558
2026-08-24 Dahlquist Karl S. · Chief Legal Officersell9,370$458,099
2026-08-05 Prange Karen · Directorsell3,564$138,283
2026-08-05 Yuen Maggie · Directorsell3,500$134,470
2026-07-30 CARREL MICHAEL H · President, CEO, & Director, Directorgift700

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What analysts expect
Strong buy3
Buy4
Hold3
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
AtriCure, Inc. (ATRC) — The Tape